Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Advanced Solid Tumors 40Advanced Solid Tumor 24Solid Tumors 23Mesothelioma, Malignant 14Mesothelioma 14Solid Tumor 12Hematopoietic and Lymphatic System Neoplasm 12Ovarian Neoplasms 8Malignant Solid Neoplasm 7Pancreatic Neoplasms 6Solid Tumours 5Solid Tumor, Adult 5Neoplasms 5Colorectal Neoplasms 5Stomach Neoplasms 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumour 4Triple Negative Breast Neoplasms 3Sarcoma 3Retinoblastoma 3Kidney Neoplasms 3Advanced or Metastatic Solid Tumors 3Advanced Malignant Solid Tumors 3Advanced Malignant Solid Neoplasm 3Thymoma 2Solitary Fibrous Tumor, Pleural 2Solid Tumor Malignancies 2Solid Tumor Cancer 2Small Cell Lung Carcinoma 2

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Locally Advanced or Metastatic Solid Tumors × Other solid neoplasm × 30 days × Clear all
NCT07469774 2026-05-28

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Biocity Biopharmaceutics Co., Ltd.

Phase 1/2 Recruiting
111 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT07607054 2026-05-26

A First-in-human Phase I Study to Evaluate EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors.

Shanghai EpimAb Biotherapeutics Co., Ltd.

Phase 1 Not yet recruiting
50 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡